Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Angiohematopoietic Progenitor Cells

a technology of angiohematopoietic progenitor cells and angiohematopoietic stem cells, which is applied in the field of angiohematopoietic stem cells, can solve the problems of limited utility of human psc cultures and significant challenge in hpsc culture identification

Inactive Publication Date: 2013-03-07
WISCONSIN ALUMNI RES FOUND
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is a purified human cell population with specific markers that can differentiate into blood cells and endothelial cells. This population can be obtained by culturing pluripotent stem cells and sorting them based on specific markers. The purified cell population can be used for various treatments such as bone marrow transplantation, blood transfusion, immunotherapy, and treatment of cardiovascular diseases. The invention also provides a method for examining the effect of drugs on cell differentiation and provides a way to supplement the patient's blood cells and endothelial cell activity.

Problems solved by technology

Because these criteria cannot be entirely applied to cells differentiated in vitro, the precise identification of HE in hPSC cultures remained as a significant challenge.
Although VE-cadherin+CD41a− and / or CD45− phenotype is commonly used for detection and isolation of HE, it has very limited utility in human PSC cultures since it covers the entire population of endothelial cells, does not fully exclude hematopoietic cells, and does not discriminate between endothelial lineages with restricted primitive hematopoietic and multipotential definitive potentials.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Angiohematopoietic Progenitor Cells
  • Angiohematopoietic Progenitor Cells
  • Angiohematopoietic Progenitor Cells

Examples

Experimental program
Comparison scheme
Effect test

examples

Introduction

[0069]In the examples below, we show that HE progenitors (HEPs) can be generated from hPSCs and be identified precisely based on VE-cadherin (CD144) expression but the lack of CD73 and CD235a / CD43 expression. We demonstrate that HEPs represent a transient population of cells with the stroma-dependent capacity to generate the entire spectrum of myeloid progenitors including β-hemoglobin producing erythroid cells and pan-myeloid CFC-GEMM. In addition, we found that the earliest VE-cadherin+CD73−CD43lowCD235a+CD41a− blood cells retain endothelial potential and possess a unique FGF2-dependent hematopoietic colony-forming activity. A novel population of endothelial progenitors lacking hematopoietic potential (non-HEPs) was distinctively recognized by the expression of CD73 and a high level of CD117, i.e. VE-cadherin+CD73+CD235a / CD43−CD117high phenotype. VE-cadherin+CD73−CD43 / CD235a−HE cells originated from EMHlin−KDRbrightAPLNR+PDGFRαlow / − hematovascular mesodermal precursors...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
densitiesaaaaaaaaaa
frequencyaaaaaaaaaa
imagingaaaaaaaaaa
Login to View More

Abstract

A purified human cell population of subsets of angiohematopoietic progenitor cells, wherein the population is at least 94% pure and wherein the cells are selected with cell markers selected from the group of KDR, APLNR, VE-cadherin, PDGFRα, CD31, CD235a, CD73, CD43, and CD41a.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Application Ser. No. 61 / 526,520, filed Aug. 23, 2011, which is incorporated herein by reference in its entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT[0002]This invention was made with government support under HL081962 and HL099773 awarded by the National Institutes of Health. The government has certain rights in the invention.BACKGROUND[0003]Establishing a system for de novo generation of hematopoietic stem cells (HSCs) from human pluripotent stem cells (hPSCs) would open a unique opportunity to study human HSC development and provide a novel source of therapeutic cells for blood disease. Achieving this goal requires a detailed understanding of cellular and molecular pathways that lead to blood formation from hPSCs and identification of the immediate precursors of multipotential hematopoietic cells.[0004]Avian, mouse and human embryonic studies demonstrated tha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12N5/071A61P9/10A61P7/00A61P9/00C12Q1/02A61K35/12
CPCC12N5/0647C12N5/0692C12N2506/45C12N2506/02C12N2502/1394A61P7/00A61P9/00A61P9/10A61K35/28A61K2035/124G01N33/502G01N33/5073
Inventor SLUKVIN, IGORVODYANYK, MAKSYMCHOI, KYUNG-DAL
Owner WISCONSIN ALUMNI RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products